JP2005515236A5 - - Google Patents

Download PDF

Info

Publication number
JP2005515236A5
JP2005515236A5 JP2003561501A JP2003561501A JP2005515236A5 JP 2005515236 A5 JP2005515236 A5 JP 2005515236A5 JP 2003561501 A JP2003561501 A JP 2003561501A JP 2003561501 A JP2003561501 A JP 2003561501A JP 2005515236 A5 JP2005515236 A5 JP 2005515236A5
Authority
JP
Japan
Prior art keywords
composition
west nile
vaccine
virus
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003561501A
Other languages
English (en)
Japanese (ja)
Other versions
JP4718778B2 (ja
JP2005515236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/023447 external-priority patent/WO2003061555A2/en
Publication of JP2005515236A publication Critical patent/JP2005515236A/ja
Publication of JP2005515236A5 publication Critical patent/JP2005515236A5/ja
Application granted granted Critical
Publication of JP4718778B2 publication Critical patent/JP4718778B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003561501A 2001-07-27 2002-07-23 ウエストナイルワクチン Expired - Lifetime JP4718778B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
US60/308,334 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010255105A Division JP2011057692A (ja) 2001-07-27 2010-11-15 ウエストナイルワクチン

Publications (3)

Publication Number Publication Date
JP2005515236A JP2005515236A (ja) 2005-05-26
JP2005515236A5 true JP2005515236A5 (https=) 2009-04-09
JP4718778B2 JP4718778B2 (ja) 2011-07-06

Family

ID=27613166

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003561501A Expired - Lifetime JP4718778B2 (ja) 2001-07-27 2002-07-23 ウエストナイルワクチン
JP2010255105A Pending JP2011057692A (ja) 2001-07-27 2010-11-15 ウエストナイルワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010255105A Pending JP2011057692A (ja) 2001-07-27 2010-11-15 ウエストナイルワクチン

Country Status (24)

Country Link
US (8) US7153513B2 (https=)
EP (3) EP2281572A1 (https=)
JP (2) JP4718778B2 (https=)
KR (2) KR20090053967A (https=)
CN (2) CN1273189C (https=)
AU (1) AU2002365244B2 (https=)
BE (1) BE2014C006I2 (https=)
BR (1) BRPI0211492B1 (https=)
CA (1) CA2452545C (https=)
CY (1) CY2014010I2 (https=)
DK (1) DK1427444T3 (https=)
ES (1) ES2435095T3 (https=)
FR (1) FR14C0016I2 (https=)
HR (1) HRP20040195B1 (https=)
HU (2) HU228690B1 (https=)
LU (1) LU92348I2 (https=)
ME (1) ME00491B (https=)
MX (1) MXPA04000680A (https=)
NZ (3) NZ570270A (https=)
PL (2) PL212212B1 (https=)
PT (1) PT1427444E (https=)
RS (1) RS53184B (https=)
WO (1) WO2003061555A2 (https=)
ZA (1) ZA200401596B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
HU228690B1 (en) * 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
US7585621B2 (en) * 2003-09-09 2009-09-08 Idexx Laboratories, Inc. Detection of West Nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
WO2006029300A2 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
WO2006107655A2 (en) * 2005-04-01 2006-10-12 Wyeth Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
CA2612047C (en) * 2005-06-24 2015-05-12 Intervet International B.V. Inactivated chimeric vaccines and related methods of use
CN101563361B (zh) * 2005-10-19 2014-01-29 佛罗里达大学研究基金公司 能够感染犬科动物的流感病毒及其用途
EP1941033A2 (en) * 2005-10-20 2008-07-09 Wyeth a Corporation of the State of Delaware Compositions and methods for the treatment of canine influenza virus disease
EP2026839A4 (en) * 2005-12-14 2009-04-01 Univ Oklahoma RNA VIRUS VACCINE AND METHODS
CA2881717C (en) * 2006-06-06 2018-06-12 Cecilia Anna Wilhelmina Geuijen Human binding molecules having killing activity against staphylococci and uses thereof
UA98812C2 (ru) 2007-11-06 2012-06-25 Вайет Ллк Авирулентная активированная живая вакцина mycoplasma hyopneumoniae
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
US9642908B2 (en) * 2008-07-30 2017-05-09 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
AU2009287449B2 (en) * 2008-08-29 2015-04-30 Boehringer Ingelheim Animal Health USA Inc. West nile virus vaccine
EP2485725A2 (en) * 2009-10-07 2012-08-15 Wyeth LLC Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof
BR112013023354B1 (pt) 2011-03-14 2022-02-15 Boehringer Ingelheim Animal Health Usa Inc Composição imunogênica compreendendo cepas de vírus da rinite equina a (erav) e seu método de produção
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
SI3542819T1 (sl) * 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
HK1224177A1 (zh) * 2013-09-05 2017-08-18 硕腾服务有限责任公司 Hendra和nipah病毒g糖蛋白免疫原性組合物
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
US12350328B2 (en) 2019-02-27 2025-07-08 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (EIV) in horses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
PT759780E (pt) * 1994-05-10 2001-01-31 American Home Prod Vacina melhorada de vsrb vivo modificado
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
IL139844A0 (en) 1998-06-04 2002-02-10 Us Gov Health & Human Serv Nucleic acid vaccines for prevention of flavivirus infection
AU2002211490A1 (en) * 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
AU2002305028A1 (en) 2001-02-28 2002-10-28 Brown University Research Foundation West nile virus epitopes and uses thereof
WO2002072036A2 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
HU228690B1 (en) * 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
AU2003263853A1 (en) 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens

Similar Documents

Publication Publication Date Title
JP2005515236A5 (https=)
Nunberg et al. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.
Dhakal et al. Nanoparticle-based vaccine development and evaluation against viral infections in pigs
Maynard Hepatitis B: global importance and need for control
Bielinska et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge
Klinman et al. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases
JP4718778B2 (ja) ウエストナイルワクチン
CA2189979A1 (en) Improved modified live brsv vaccine
Podda et al. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile
Gasparini et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects
AU766635B2 (en) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
JP2026026092A5 (https=)
CA2383105A1 (en) Intranasal influenza virus vaccine
Strube et al. A gE deleted infectious bovine rhinotracheitis marker vaccine for use in improved bovine herpesvirus 1 control programs
EP1265633B1 (de) Adjuvans für vakzinen
CA2457563A1 (en) Interleukin-12 as a veterinary vaccine adjuvant
AR041171A1 (es) Modulador inmune
EP1154792B1 (en) Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
Simms et al. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs
EP0604727A1 (en) Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen
WO2005016246A3 (en) Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
WO1998046263A1 (en) Saponin adjuvants in combination with dna vaccination
MX2025011740A (es) Composiciones de coronavirus e influenza y metodos para su uso
CN101466370A (zh) 纳米乳剂疫苗
Wyde et al. Immunogenicity and protection in mice given inactivated influenza vaccine, MPL, QS-21 or QS-7